SCS Capital Management’s Novo Nordisk NVO Stock Holding History

SCS Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$370K	Buy	7,711 +206	+3%	+$8.85K	﹤0.01%	396
2026 Q1	$284K	Sell	7,505 -129,094	-95%	-$6.12M	﹤0.01%	420
2025 Q4	$6.95M	Buy	136,599 +409	+0.3%	+$20.9K	0.07%	124
2025 Q3	$7.56M	Buy	136,190 +126,891	+1,365%	+$7.43M	0.08%	119
2025 Q2	$642K	Buy	9,299 +2,164	+30%	+$147K	0.01%	342
2025 Q1	$503K	Buy	+7,135	New	+$589K	0.01%	347

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

SCS Capital Management's NVO Position: Q2 2026 in Review

SCS Capital Management increased its Novo Nordisk (NVO) stake by 2.7% in Q2 2026, buying an estimated $8.85K and bringing the position to 7,711 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #396.

SCS Capital Management first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.56M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

SCS Capital Management held 7,711 shares of Novo Nordisk worth $370K as of Q2 2026.
SCS Capital Management bought 206 Novo Nordisk shares in Q2 2026, an estimated $8.85K.
Novo Nordisk made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #396 holding.
SCS Capital Management first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
SCS Capital Management's Novo Nordisk position peaked at $7.56M in Q3 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.